Pinduoduo Turns To Profit In Q3 On Strong Revenue Growth - Quick Facts

Pinduoduo Inc. (PDD), China's largest agriculture and interactive commerce platform, reported Friday that third-quarter net income attributable to ordinary shareholders was 1.64 billion Chinese yuan or $254.5 million, compared to net loss of 784.7 million yuan last year.

Earnings per ADS were 1.15 yuan or $0.18, compared to last year's net loss per ADS of 0.66 yuan.

Adjusted net income attributable was 3.15 billion yuan or $488.9 million, compared to 466.4 million yuan in the same quarter of 2020. Adjusted earnings per ADS were 2.18 yuan or $0.34, compared to 0.33 yuan in the same quarter of 2020.

Total revenues in the quarter were 21.51 billion yuan or $3.34 billion, an increase of 51 percent from 14.21 billion yuan a year ago.

Average monthly active users in the quarter was 741.5 million, an increase of 15 percent from 643.4 million in 2020.

Active buyers in the twelve-month period ended September 30 was 867.3 million, up 19 percent from the same period last year.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Longmont Colorado -based Royal Crest Dairy is recalling 2% Chocolate Milk citing the potential to be contaminated with undeclared egg, a known allergen, the U.S. Food and Drug Administration said. The recall involves Farmer's 2% Reduced Fat Chocolate Milk Pints with the code date of AUG-22. ANI Pharmaceuticals, Inc. (ANIP) Monday announced a wider loss for the second quarter, despite a 52 percent surge in revenues. For the full year 2022, the company reiterated the adjusted earnings per share range, revenue guidance and raised Cortrophin revenue outlook. The company reported a quarterly... Shares of BioNTech SE were losing around 4 percent in the morning trading in Germany and around 5 percent in the pre-market activity on Nasdaq after the German Covid-19 vaccine maker reported sharp drop in profit and revenues for the second quarter. However, the company recorded strong growth in first-half results. Further, the company maintained BioNTech COVID-19 vaccine revenue guidance
Follow RTT